Results 71 to 80 of about 17,823 (170)
Nanoprobe‐Enabled Precision Imaging and Panoramic Boundary Delineation in Retinoblastoma
Cancer Innovation, Volume 5, Issue 5, October 2026.This review highlights that nanoprobe‐enabled multimodal imaging, combined with targeted probe design and AI‐assisted analysis, significantly enhances the precise visualization and boundary delineation of retinoblastoma. It further outlines key challenges and directions for translating high‐performance imaging nanoprobes into clinical practice.
Xuefei He +7 more
wiley +1 more source
Preclinical pharmacology and clinical uses of topotecan
, 1999 Topotecan, a soluble semisynthetic derivative of camptothecin, is a specific inhibitor of topoisomerase I and is endowed of potent antiproliferative effect in vitro and in vivo on tumoral cell lines as well as on endothelial cells. Moreover, topotecan is
DEL TACCA M +2 more
core +2 more sources
Case Reports in Oncology, 2014 Introduction: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease.
Donato Callegaro-Filho +4 more
doaj +1 more source
CDS2 Drives Tumor Progression in Epithelial Ovarian Cancer via the PI3K/AKT Pathway
Cancer Medicine, Volume 15, Issue 10, October 2026.ABSTRACT Background Epithelial ovarian cancer (EOC) frequently disseminates within the lipid‐rich peritoneal cavity, where tumor progression is accompanied by metabolic adaptations involving lipid utilization and mitochondrial function. Although these metabolic alterations are increasingly recognized as important features of EOC progression and ...
Lixue Cao +10 more
wiley +1 more source
International Journal of Cancer, Volume 159, Issue 7, Page 1735-1749, 1 October 2026.The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg +9 more
wiley +1 more source
Thoracic Cancer, Volume 17, Issue 20, October 2026.This systematic review and meta‐analysis evaluated the efficacy and safety of trilaciclib for preventing chemotherapy‐induced myelosuppression in patients with solid tumors. Trilaciclib significantly reduced severe neutropenia, febrile neutropenia, and supportive care requirements with a possible overall survival benefit and no apparent compromise in ...
Wei Tian +3 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 10, October 2026.ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju +6 more
wiley +1 more source
Pediatric Blood &Cancer, Volume 73, Issue 9, September 2026.ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot +6 more
wiley +1 more source
Advanced Science, Volume 13, Issue 49, 3 September 2026.A multifunctional nanoagonist (cDZ@IP) enables nano‐metabolite–driven multimodal activation of the STING pathway and enhanced immune recognition, achieving potent antitumor immunity and suppressing tumor growth and metastasis. This strategy highlights the rational design of therapeutic metabolites and establishes a new paradigm bridging nanomedicine ...
Kepeng Hu +17 more
wiley +1 more source
Frontiers in Cell and Developmental Biology, 2020 While topotecan (TPT) is a first- and second-line chemotherapeutic drug in treating lung cancer, the development of drug resistance in tumors still reserves as a major obstacle to chemotherapeutic success.
Zi-Ning Lei +12 more
doaj +1 more source